A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Marika, Yakushijin, Kimikazu, Funakoshi, Yohei, Ohji, Goh, Ichikawa, Hiroya, Sakai, Hironori, Hojo, Wataru, Saeki, Miki, Hirakawa, Yuri, Matsumoto, Sakuya, Sakai, Rina, Nagao, Shigeki, Kitao, Akihito, Miyata, Yoshiharu, Koyama, Taiji, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Murayama, Tohru, Matsuoka, Hiroshi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/
https://www.ncbi.nlm.nih.gov/pubmed/36366338
http://dx.doi.org/10.3390/vaccines10111830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/
https://www.ncbi.nlm.nih.gov/pubmed/36366338
http://dx.doi.org/10.3390/vaccines10111830

Ejemplares similares